Revolution Medicines publishes corporate deck outlining RAS(ON) inhibitor pipeline targeting RAS-driven cancers
Reuters2026/08/05 22:01- Revolution Medicines highlighted Phase 3 RASolute 302 data in previously treated metastatic pancreatic cancer for daraxonrasib versus IV chemotherapy.
- Overall survival hazard ratio 0.40, a 60% reduction in risk of death; median OS 13.2 months versus 6.7 months.
- U.S. FDA accepted the daraxonrasib NDA for review; EMA began a phased review of the marketing authorization application.
- Expanded access program supplied daraxonrasib for physicians on behalf of more than 2,000 patients across almost all 50 states.
- Pipeline update centered on oral RAS(ON) inhibitors, including zoldonrasib in combination regimens for KRAS G12D pancreatic cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The first major "exam" after the Cook era! Morgan Stanley: Apple's (AAPL.US) autumn launch event is the most important in ten years; the first foldable iPhone may spark a new wave of growth
Morgan Stanley analysts stated that Apple's upcoming "Surprise and Shine" autumn product launch event on September 9 may become the company's most important product release in nearly a decade.
10-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - Germany vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
